Related Experiment Video

Updated: Jun 12, 2026

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
09:37

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients

Constantin Roder1, Vera Peters, Hidetoshi Kasuya

  • 1Department of Neurosurgery, University of Tübingen, Germany.

Acta Neurochirurgica
|June 24, 2010
PubMed
Abstract

Insights

Genetic variations in Transforming Growth Factor Beta 1 (TGFB1) and Platelet Derived Growth Factor Receptor Beta (PDGFRB) may increase Moyamoya disease (MMD) risk. Further research could enable early detection and prevention of MMD.

Area of Science:

  • Genetics
  • Vascular Biology
  • Neurology

Background:

  • Moyamoya disease (MMD) etiology remains largely unknown.
  • Previous studies suggest altered cytokine and growth factor levels in MMD patients.
  • This study investigates genetic predispositions by analyzing single nucleotide polymorphisms (SNPs) in relevant genes.

Purpose of the Study:

  • To identify potential genetic risk factors for Moyamoya disease (MMD).
  • To analyze single nucleotide polymorphisms (SNPs) in genes encoding specific cytokines and growth factors associated with MMD.
  • To compare genetic profiles of MMD patients with healthy controls.

Main Methods:

  • Genotyping of thirteen single nucleotide polymorphisms (SNPs) in or upstream of four genes: BFGF, CRABP1, PDGFRB, and TGFB1.
  • Analysis of DNA samples from 40 MMD patients and 68 healthy central European controls.
  • SNP genotyping was performed using sequencing of SNP-containing genetic regions with custom primers.

Main Results:

  • Association found between two SNPs and MMD risk.
  • rs382861 (A/C) in the PDGFRB promoter region showed a significant association (p=0.0373, OR=1.81).
  • rs1800471 (C/G) in the TGFB1 first exon was also associated with MMD (p=0.0345, OR=7.65).

Conclusions:

  • The study suggests potential genetic risk factors for Moyamoya disease (MMD) development.
  • TGFB1 and PDGFRB genes, involved in vascular processes, may play a role in MMD pathogenesis.
  • Further studies in larger, diverse cohorts and functional analyses are recommended for early detection and preventive strategies.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Genetic Lingo01:11

Genetic Lingo

Overview
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life